🔎 Trials Near Me

Akèy › Lukemi lenfositè kwonik › Utah › Salt Lake City

Etid klinik pou Lukemi lenfositè kwonik nan Salt Lake City, UT

10 etid pou Lukemi lenfositè kwonik ap chèche patisipan nan sit nan ak bò kote Salt Lake City (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.

Tèks ofisyèl etid la (Anglè)

Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

Ap rekriteFaz 3
  • Huntsman Cancer Institute/University of Utah, Salt Lake City
Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT04269902

A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia

Ap rekriteFaz 3
  • Huntsman Cancer Institute, Salt Lake City
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT07277231

A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)

Ap rekriteFaz 2
  • University of Utah, Salt Lake City
Laj 18 ak plis · Tout sèks · Mizajou Sep 17, 2026 · NCT07221500

Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia

Ap rekriteFaz 2
  • Huntsman Cancer Institute/University of Utah, Salt Lake City
Laj 18 ak plis · Tout sèks · Mizajou Sep 11, 2026 · NCT07061951

A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia

Ap rekriteFaz 1
  • Huntsman Cancer Institute at The University of Utah, Salt Lake City
Laj 18 ak plis · Tout sèks · Mizajou Sep 8, 2026 · NCT05091424

Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.

Ap rekriteFaz 1
  • University of Utah, Salt Lake City
Laj 13 ak plis · Tout sèks · Mizajou May 5, 2026 · NCT04771572

Pneumococcal Pneumonia Vaccine Series (PCV20 and PPSV23) in Patients With Chronic Lymphocytic Leukemia Associated Immunodeficiency, PROTECT CLL Trial

Ap rekriteFaz 2
  • Huntsman Cancer Institute/University of Utah, Salt Lake City
Laj 18 ak plis · Tout sèks · Mizajou Apr 9, 2026 · NCT05183854

A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies

Ap rekriteFaz 1
  • Huntsman Cancer Institute, University of Utah, Salt Lake City
Laj 18 ak plis · Tout sèks · Mizajou Mar 20, 2026 · NCT04830137

Effects of Nicotinamide in Patients With Chronic Lymphocytic Leukemia With History of Non-melanoma Skin Cancers

Ap rekriteFaz 2
  • Huntsman Cancer Institute at University of Utah, Salt Lake City
Laj 18 ak plis · Tout sèks · Mizajou Dec 3, 2025 · NCT04844528

A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies

Ap rekriteFaz 1/2
  • University of Utah, Salt Lake City
Laj 18 ak plis · Tout sèks · Mizajou Nov 14, 2025 · NCT05643742

Etid Lukemi lenfositè kwonik nan lòt vil

Lòt etid nan Salt Lake City

Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.